Next Article in Journal
Feasibility of a Remotely Delivered Strength and Balance Training Program for Older Adults with Cancer
Next Article in Special Issue
Immunotherapy in the First-Line Setting in Wild-Type NSCLC
Previous Article in Journal
Parents’ Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study
Previous Article in Special Issue
Immunotherapy in Extensive-Stage Small Cell Lung Cancer
Review

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer

1
Department of Oncology, McMaster University, 699 Concession Street, Hamilton, ON L8V 5C2, Canada
2
Escarpment Cancer Research Institute, McMaster University, Hamilton, ON L8V 5C2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(6), 4392-4407; https://doi.org/10.3390/curroncol28060373
Received: 27 September 2021 / Revised: 19 October 2021 / Accepted: 31 October 2021 / Published: 2 November 2021
(This article belongs to the Special Issue Current State of Immunotherapy for Lung Cancer)
Cancer immunotherapy has the goal of enhancing a patient’s intrinsic immune processes in order to mount a successful immune response against tumor cells. Cancer cells actively employ tactics to evade, delay, alter, or attenuate the anti-tumor immune response. Immune checkpoint inhibitors (ICIs) modulate endogenous regulatory immune mechanisms to enhance immune system activation, and have become the mainstay of therapy in many cancer types. This activation occurs broadly and as a result, activation is supraphysiologic and relatively non-specific, which can lead to immune-related adverse events (irAEs), the frequency of which depends on the patient, the cancer type, and the specific ICI antibody. Careful assessment of patients for irAEs through history taking, physical exam, and routine laboratory assessments are key to identifying irAEs at early stages, when they can potentially be managed more easily and before progressing to higher grades or more serious effects. Generally, most patients with low grade irAEs are eligible for re-challenge with ICIs, and the use of corticosteroids to address an irAE is not associated with poorer patient outcomes. This paper reviews immune checkpoint inhibitors (ICIs) including their mechanisms of action, usage, associated irAEs, and their management. View Full-Text
Keywords: immune checkpoint inhibitor; re-challenge; immunosuppression; immune-related adverse events immune checkpoint inhibitor; re-challenge; immunosuppression; immune-related adverse events
Show Figures

Figure 1

MDPI and ACS Style

Coschi, C.H.; Juergens, R.A. The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. Curr. Oncol. 2021, 28, 4392-4407. https://doi.org/10.3390/curroncol28060373

AMA Style

Coschi CH, Juergens RA. The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. Current Oncology. 2021; 28(6):4392-4407. https://doi.org/10.3390/curroncol28060373

Chicago/Turabian Style

Coschi, Courtney H., and Rosalyn A. Juergens. 2021. "The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer" Current Oncology 28, no. 6: 4392-4407. https://doi.org/10.3390/curroncol28060373

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop